Population Pharmacokinetic and Exposure–Response Analyses for Ponatinib in the Phase 3 PhALLCON Study
Sign Up to like & getrecommendations! Published in 2025 at "Clinical and Translational Science"
DOI: 10.1111/cts.70175
Abstract: In March 2024, ponatinib received accelerated FDA approval for the treatment of newly diagnosed Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph + ALL) in combination with chemotherapy based on the Phase 3 PhALLCON study (NCT03589326), which demonstrated a… read more here.
Keywords: phallcon study; phallcon; mrd negative; population ... See more keywords